Boxin Xue

Prof. Boxin Xue

The Second Affiliated Hospital of Soochow University, China Lake Acres, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2023 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
LJLu Jin
Lu Jin
JZJin Zhu
Jin Zhu
LYLinya Yao
Linya Yao
ASand Gang Shen
and Gang Shen
BXBoxin Xue
Boxin Xue
WTWei Tao
Wei Tao
Sphingosine kinases (SphK), including SphK1 and SphK2, are important enzymes promoting progression of prostate cancer. SKI-178 is a novel and highly potent SphK1/2 dual inhibitor. We here tested the potential anti-prostate cancer cell activity of SKI-178. Bioinformatics analyses and results from local tissues demonstrated that that both SphK1 and SphK2 are upregulated in human prostate cancer tissues. Ectopic overexpression of SphK1 and SphK2, by lentiviral constructs, promoted primary prostate cancer cell proliferation and migration. In primary human prostate cancer cells and immortalized cell lines, SKI-178 potently inhibited cell viability, proliferation, cell cycle progression and cell migration, causing robust cell death and apoptosis. SKI-178 impaired mitochondrial functions, causing mitochondrial depolarization, reactive oxygen species production and ATP depletion.SKI-178 potently inhibited SphK activity and induced ceramide production, without affecting SphK1/2 expression in prostate cancer cells. Further, SKI-178 inhibited Akt-mTOR activation and induced JNK activation in prostate cancer cells. Contrarily, a constitutively-active Akt1 construct or the pharmacological JNK inhibitors attenuated SKI-178-induced cytotoxicity in prostate cancer cells. In vivo, daily intraperitoneal injection of a single dose of SKI-178 potently inhibited PC-3 xenograft growth in nude mice. SphK inhibition, ceramide production, ATP depletion and lipid peroxidation as well as Akt-mTOR inactivation and JNK activation were detected in PC-3 xenograft tissues with SKI-178 administration. Together, targeting SphK1/2 by SKI-178 potently inhibited prostate cancer cell growth in vitro and in vivo.

16 March 2022 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
LJLu Jin
Lu Jin
WZWei Zhang
Wei Zhang
MYMing-Yu Yao
Ming-Yu Yao
YTYe Tian
Ye Tian
BXBoxin Xue
Boxin Xue
WTWei Tao
Wei Tao
GNE-493 is a novel PI3K/mTOR dual inhibitor with improved metabolic stability, oral bioavailability, and excellent pharmacokinetic parameters. Here GNE-493 potently inhibited viability, proliferation, and migration in different primary and established (LNCaP and PC-3 lines) prostate cancer cells, and provoking apoptosis. GNE-493 blocked Akt-mTOR activation in primary human prostate cancer cells. A constitutively-active mutant Akt1 restored Akt-mTOR activation but only partially ameliorated GNE-493-induced prostate cancer cell death. Moreover, GNE-493 was still cytotoxic in Akt1/2-silenced primary prostate cancer cells. Significant oxidative stress and programmed necrosis cascade activation were detected in GNE-493-treated prostate cancer cells. Moreover, GNE-493 downregulated Sphingosine Kinase 1 (SphK1), causing ceramide accumulation in primary prostate cancer cells. Daily single dose GNE-493 oral administration robustly inhibited the growth of the prostate cancer xenograft in the nude mice. Akt-mTOR inactivation, SphK1 downregulation, ceramide level increase, and oxidative injury were detected in GNE-493-treated prostate cancer xenograft tissues. Together, GNE-493 inhibited prostate cancer cell growth possibly through the Akt-mTOR-dependent and -independent mechanisms.

24 May 2023 in Aging
Verified
Journal Article
Open access
PDF file
LRLingxiang Ran
Lingxiang Ran
ZGZhixiang Gao
Zhixiang Gao
QCQiu Chen
Qiu Chen
FCFengmei Cui
Fengmei Cui
XLXiaolong Liu
Xiaolong Liu
BXBoxin Xue
Boxin Xue
Non-obstructive azoospermia (NOA) is a common cause of male infertility, and no specific diagnostic indicators exist. In this study, we used human testis datasets GSE45885, GSE45887, and GSE108886 from GEO database as training datasets, and screened 6 signature genes (all lowly expressed in the NOA group) using Boruta algorithm and Lasso regression: C12orf54, TSSK6, OR2H1, FER1L5, C9orf153, XKR3. The diagnostic efficacy of the above genes was examined by constructing models with LightGBM algorithm: the AUC (Area Under Curve) of both ROC and Precision-Recall curves for internal validation was 1.0 (p < 0.05). For the external validation dataset GSE145467 (human testis), the AUC of its ROC curve was 0.9 and that of its Precision-Recall curve was 0.833 (p < 0.05). Next, we confirmed the cellular localization of the above genes using human testis single-cell RNA sequencing dataset GSE149512, which were all located in spermatid. Besides, the downstream regulatory mechanisms of the above genes in spermatid were inferred by GSEA algorithm: C12orf54 may be involved in the repression of E2F-related and MYC-related pathways, TSSK6 and C9orf153 may be involved in the repression of MYC-related pathways, while FER1L5 may be involved in the repression of spermatogenesis pathway. Finally, we constructed a NOA model in mice using X-ray irradiation, and quantitative Real-time PCR results showed that C12orf54, TSSK6, OR2H1, FER1L5, and C9orf153 were all lowly expressed in NOA group. In summary, we have identified novel signature genes of NOA using machine learning methods and complete experimental validation, which will be helpful for its early diagnosis.

22 January 2022 in Journal of X-Ray Science and Technology
Verified
Journal Article
Closed access
PDF file
WTWei Tao
Wei Tao
XMXu Ming
Xu Ming
YZYachen Zang
Yachen Zang
JZJin Zhu
Jin Zhu
YZYuanyuan Zhang
Yuanyuan Zhang
BXBoxin Xue
Boxin Xue
PURPOSE: To evaluate efficacy and safety of flexible ureteroscopy and laser lithotripsy (FURSL) for treatment of the upper urinary tract calculi. METHODS: We retrospectively analyzed 784 patients who underwent FURSL between January 2015 and October 2020 in our unit. All patients were preoperatively evaluated with urine analysis, serum biochemistry, urinary ultrasonography, non-contrast computed tomography and intravenous urography. The procedure was considered as successful in patients with complete stone disappearance or fragments < 4 mm on B ultrasound or computed tomography. The operative parameters, postoperative outcomes and complications were recorded and analyzed respectively. RESULTS: The average operative time and postoperative hospital stay were 46.9±15.8 min and 1.2±1.1 days, respectively, among 784 patients. In addition, 746 patients were followed up and 38 patients were lost. In these patients, 700 (93.8%) cases met the stone removal criteria and 46 cases (6.2%) did not meet the stone removal criteria who need further treatment. The stone free rate (SFR) is 92.5%after 1–3 months and SFR of middle and upper calyceal calculi was higher than that of lower calyceal calculi significantly. The most common complications were fever (58/784, 7.4%), gross hematuria (540/784, 68.9%) and lpsilateral low back pain (47/784, 6.0%). The incidence rate of serious complication was 1.28%(10/784), including 5 cases of septic shock and 5 cases of subcapsular hematoma, which were cured after active treatment. CONCLUSION: FURSL is a reliable treatment for small and medium calculi patients of upper urinary tract. The curative effect of stone removal is clear. The complications are few and the safety is high. However, there are certain limitations to the efficacy in treating larger stone and lower calyceal calculi.

24 April 2023 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
LRLingxiang Ran
Lingxiang Ran
ZGZhixiang Gao
Zhixiang Gao
QCQiu Chen
Qiu Chen
YRYuanshuai Ran
Yuanshuai Ran
NDNengliang Duan
Nengliang Duan
BXBoxin Xue
Boxin Xue

22 June 2020 in Photobiomodulation, Photomedicine, and Laser Surgery
Verified
Journal Article
Closed access
XLXiaolong Liu
Xiaolong Liu
FYFeng Yuan
Feng Yuan
BXBoxin Xue
Boxin Xue
Purpose: To evaluate the safety and efficacy of GreenLight XPS 180-W laser photoselective vaporization of the prostate (PVP) in high-risk elderly patients with benign prostatic hyperplasia. Materials and methods: This retrospective study included 150 elderly patients with enlarged prostate glands (>40 mL) receiving 180-W photoselective vaporization at our department between January 2016 and October 2018. All patients were of advanced age (>80 years) and included those at higher risk of bleeding and cardiopulmonary disease. Perioperative data were collected and analyzed. Results: All operations were completed uneventfully without conversion to open surgery, and nobody died due to postoperative complications. The mean preoperative prostate volume was 65 ± 12.5 mL, mean operative time was 63 ± 12.5 min, mean laser working time was 51 ± 9.2 min, and mean catheterization time was 2.7 ± 1.8 days. There were significant improvements in International Prostate Symptom Scores, quality of life, maximum flow rate, and postvoid residual volume compared with preoperative values. Intraoperative as well as short- and long-term postoperative complication rates were 0.7%, 29.8%, and 13.3%, respectively. Three patients required rehospitalization for postoperative complications, one needed reoperation, and the others recovered after conservative treatment. Conclusions: PVP with a GreenLight XPS 180-W laser in high-risk elderly patients is safe and feasible. It provides a dramatic improvement in both short- and long-term functional outcomes and deserves promotion.